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Abstract
Background: The potential pathogenetic significance of mitochondrial DNA (mtDNA) mutations
in tumorigenesis is controversial. We hypothesized that benign tumorigenesis of a slowly
replicating tissue like the human parathyroid might constitute an especially fertile ground on which
a selective advantage conferred by mtDNA mutation could be manifested and might contribute to
the oxyphilic phenotype observed in a subset of parathyroid tumors.
Methods: We sought acquired mitochondrial DNA mutations by sequencing the entire 16.6 kb
mitochondrial genome of each of thirty sporadic parathyroid adenomas (18 chief cell and 12 oxyphil
cell), eight independent, polyclonal, parathyroid primary chief cell hyperplasias plus corresponding
normal control samples, five normal parathyroid glands, and one normal thyroid gland.
Results: Twenty-seven somatic mutations were identified in 15 of 30 (9 of 12 oxyphil adenomas,
6 of 18 chief cell) parathyroid adenomas studied. No somatic mutations were observed in the
hyperplastic parathyroid glands.
Conclusion: Features of the somatic mutations suggest that they may confer a selective advantage
and contribute to the molecular pathogenesis of parathyroid adenomas. Importantly, the
statistically significant differences in mutation prevalence in oxyphil vs. chief cell adenomas also
suggest that mtDNA mutations may contribute to the oxyphil phenotype.
Background
Single parathyroid adenomas, which cause approximately
85% of the cases of primary hyperparathyroidism [1] are
well-differentiated, benign, clonal tumors, which produce
hypercalcemia through excessive secretion of parathyroid
hormone (PTH). Activation of the cyclin D1 oncogene and
inactivation of the MEN1  tumor suppressor gene are
established pathogenetic contributors, but understanding
of molecular pathogenesis in this disease remains incom-
plete. The mitochondrial genome has been identified as a
possible target for somatic mutations that may promote
tumorigenesis [2-10]. Mitochondrial abnormalities,
including changes in structure, number, and respiratory
enzyme components and transport systems, have been
observed in many cancers. Homoplasmic somatic muta-
tions of the mitochondrial genome have also been identi-
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fied in many tumor types [2-10]. However, the
pathogenetic significance of the mutations detected in
those tissues is unclear.
The human parathyroid is an intrinsically low-turnover
tissue [11], as such, benign tumors arising from this tissue
have relatively low proliferative rates. The mitochondrial
genome is an especially attractive potential target for
mutations that could drive tumorigenesis in such a tissue.
Mitochondrial DNA replicates frequently and independ-
ently of the nuclear genome [12], and over many years the
potential for enhanced DNA damage from locally gener-
ated reactive oxygen species (ROS) may further enhance
the accumulation of somatic mutations in the mitochon-
drial genome.
In many endocrine organs, especially the parathyroid
glands, with age, increasing numbers of oxyphil cells
appear [13,14]. The oxyphil cells of normal parathyroid
glands have a characteristic eosinophilic granular cyto-
plasm (Figure 1) which on electron microscopic examina-
tion is filled with abnormally shaped mitochondria
[15,16]. In contrast to the chief cells, the oxyphil cells in
normal glands lack the organelles associated with protein
synthesis and secretion, and lack immunohistochemically
identifiable chromogranin and PTH [16]. The majority of
parathyroid adenomas are composed predominately of
chief cells (Figure 1), however there is a subset of hyper-
functioning parathyroid adenomas that contain greater
than 90% oxyphil cells and are classified as oxyphil ade-
nomas These tumors, in addition to having a cytoplasm
filled with abnormal mitochondria, contain the
organelles of protein synthesis and secretion and contain
histochemically identifiable PTH. While the molecular
basis for this phenotypic change is unknown, it has been
hypothesized that mitochondria may accumulate in
oxyphil cells due to abnormalities of the mitochondrial
genome[17], supported by the finding of increased num-
bers of oxyphil cells in normal glands with increasing age,
analogous to increased mtDNA damage that occurs with
aging [16].
We therefore sought acquired somatic mutations of the
mitochondrial genome in both typical chief cell parathy-
roid adenomas and oxyphil cell parathyroid adenomas
using an especially rigorous approach, and compared
these findings with the mitochondrial genomes of normal
and hyperplastic parathyroid glands.
Methods
Patient and tumor samples
Tissue samples were obtained, with Human Studies Insti-
tutional Review Board approval, from thirty-four patients
who had undergone parathyroidectomy for management
of primary hyperparathyroidism. Thirty samples were sur-
gically and pathologically proven to be single parathyroid
adenomas with no malignant features; of these, eighteen
were determined to be typical chief cell adenomas and
twelve were determined to be oxyphil adenomas, defined
as containing at least 90% oxyphil cells. Eight samples
from four patients were consistent with primary chief cell
hyperplasia, involving multiple glands. None of the
patients from whom tissue was obtained had a known
history of head or neck irradiation, or a history of familial
hyperparathyroidism or multiple endocrine neoplasia.
One patient with primary chief cell hyperplasia had a his-
The chief cells of an adenoma (A) have an amphophilic, vacuolated cytoplasm, which on electron microscopic examination is  composed of sparse mitochondria and the usual organelles associated with protein synthesis and secretion, glycogen and lipid  [30] Figure 1
The chief cells of an adenoma (A) have an amphophilic, vacuolated cytoplasm, which on electron microscopic examination is 
composed of sparse mitochondria and the usual organelles associated with protein synthesis and secretion, glycogen and lipid 
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tory of lithium use. After surgical removal, tissues were
dissected and quickly frozen in liquid nitrogen before
being stored at -80°C. Peripheral blood leukocyte sam-
ples were obtained from the same patients, to serve as
non-parathyroid germline controls. Also included in this
study were five normal parathyroid glands and one nor-
mal thyroid gland from five patients with primary hyper-
parathyroidism due to a single adenoma. One normal
parathyroid gland and a normal thyroid gland were
obtained on autopsy. The remaining normal parathyroid
glands were obtained from patients who had the glands
removed incidental to an operation for thyroid disease.
Mitochondrial Genome Sequencing
Genomic DNA was extracted from each sample using
either proteinase K digestion for surgical samples or
sucrose gradient centrifugation for blood samples, fol-
lowed by phenol-chloroform extraction and ethanol pre-
cipitation.
The entire 16.6 kb mitochondrial genome from each par-
athyroid sample was amplified and sequenced. To avoid
amplification of nuclear mitochondrial pseudogenes, the
mitochondrial genome was amplified as per Polyak et al
[8], as 8 overlapping 1–3 kb PCR products using a step
down PCR protocol or as 11 overlapping PCR products
described as follows: PCR reactions were performed in 20
µl reaction volume including 25 ng DNA, 20 pmol of each
primer, 200 µM each dNTP, 1.25 U of Amplitaq Gold
DNA Polymerase (Applied Biosystems, Foster City, CA)
and 1.5 mM magnesium chloride; thermocycling con-
sisted of an initial denaturation step of 95°C for 10 min-
utes, 35 cycles of 95°C for 30 seconds, 55°C for 30
seconds, and 72°C for 3 minutes, and a final extension
step at 72°C for 10 minutes. For difficult to amplify tem-
plates, additional PCR primers were designed and are
available on request. PCR products were either gel puri-
fied using the Qiagen gel extraction kit (Qiagen, Valencia,
CA), or 10 U Exonuclease I and 1 U Shrimp Alkaline Phos-
phatase (Amersham Pharmacia Biotech, Piscataway, NJ).
Purified PCR products were subjected to automated
sequencing using the Big Dye Terminator Cycle Sequenc-
ing Ready Reaction Kit (Applied Biosystems). We also
made and utilized additional sequencing primers,
sequences available on request. Sequencing products were
purified through Sephadex G-50 columns (Sigma-Aldrich,
St. Louis, MO), and electrophoresed on 4.75% Long
Ranger gels (BioWhittaker Molecular Applications, Rock-
land, ME) on an ABI Prism 377 Sequencer (Applied Bio-
systems).
To determine if sequence changes identified in patients
with hyperparathyroidism were somatic and/or clonal,
the corresponding mitochondrial genomic regions from
the patient's normal control peripheral blood leukocytes
were also sequenced as above. Resulting sequence data
files were analyzed and compared with the standard
Anderson mtDNA sequence using the sequence analysis
programs Sequencing Analysis and Auto Assembler
(Applied Biosystems). Deviations from the standard
sequence were compared with the on-line Mitomap data-
base of previously reported mtDNA mutations and poly-
morphisms [18]. All apparent somatic clonal mutations
were confirmed by sequencing products of independent
PCR reactions, and by sequencing the opposite DNA
strand.
Results
A total of 393 homoplasmic sequence variants were iden-
tified (8–45 variants per sample) as compared to the
standard Anderson mtDNA sequence [19]. Of the 393 var-
iants, 375 were single base pair substitutions, 13 were sin-
gle base pair insertions or deletions (4 deletions and 9
insertions), 2 were 2 base pair deletions, 2 were 2 base
pair insertions and 1 was an 8 base pair deletion. Evalua-
tion utilizing the mitochondrial database, Mitomap [18],
indicated that of the 393 variants, 117 were in non-coding
regions, 244 were in protein coding genes and 32 were
predicted to affect rRNA or tRNA. Novel sequence variants
are shown in Table 1.
Eleven somatic mutations were identified in 6 of 18 chief
cell adenomas (Table 2 and Figure 2). Two tumors con-
tained mutations that were predicted to result in early stop
codons in either the ND4 or ND6 genes, both subunits of
mitochondrial Complex I. Three tumors contained muta-
tions that were predicted to result in non-synonymous
changes in subunits of either Complex I or Complex III.
Two tumors contained mutations only in the highly poly-
morphic, but non-coding D-loop region.
Sixteen somatic mutations were identified in 9 of 12
oxyphil adenomas. Four tumors contained mutations that
were predicted to result in early stop codons in either the
ND1, ND4 or ND5 genes, all subunits of mitochondrial
Complex I. Two tumors contained non-synonymous
changes in Complex I subunits, one tumor contained a
mutation in CO1 not predicted to change the amino acid
sequence and one tumor contained a mutation affecting a
tRNA gene. One tumor contained a D-loop mutation
only. All mutations appeared to be homoplasmic, with
the exception of one, which appeared to be heteroplas-
mic, a G to A transition at position 559, within the D-loop
region. Homoplasmy refers to the presence of a particular
sequence variant or mutation in virtually every copy of the
mitochondrial genome within a single tumor cell sample
(and within the limits of sensitivity of the sequencing
technology), while heteroplasmy refers to the presence of
more than one such detectable allele [20]. Heteroplasmy
within a tumor would be indistinguishable from homo-BMC Endocrine Disorders 2007, 7:8 http://www.biomedcentral.com/1472-6823/7/8
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Table 1: Novel germline sequence variants identified by this study
Nucleotide position Base Change Region Affected Expected Protein Change
1007 g-a 12s rRNA n/a
1339 g-c 12s rRNA n/a
2218 c-t 16s rRNA n/a
2639 c-t 16s rRNA n/a
3159 ins t 16s rRNA n/a
3198 a-c 16s rRNA n/a
3511 a-g ND1 69 Thr-Ala
3719 a-g ND1 138 Gln-Arg
3826 t-c ND1 no change
3867 c-t ND1 no change
4296 t-c Ile tRNA n/a
4674 a-g ND2 69 Ile-Val
4718 a-g ND2 no change
4735 c-a ND2 89 Thr-Arg
5238 c-t ND2 no change
5250 t-c ND2 no change
5318 c-t ND2 no change
5463 c-t ND2 332 Leu-Phe
6026 g-a COI 42 Gly-Asp
6339 a-g COI 146 Thr-Ala
6425 t-c COI no change
6570 g-t COI 223 Ala-Ser
6656 c-t COI no change
6775 a-c COI 291 His-Pro
7295 a-g COI no change
7744 t-c COII no change
7963 a-g COII no change
7966 c-t COII no change
8395 c-t ATPase8 no change
8515 c-t ATPase8 no change
8602 t-c ATPase6 26 Phe-Leu
8953 a-g ATPase6 143 Ile-Val
8987 t-g ATPase6 154 Met-STOP
9088 t-c ATPase6 188 Ser-Pro
9210 a-g COIII 2 Thr-Ala
9233 t-c COIII no change
9426 c-t COIII 74 Pro-Ser
9555 c-a COIII 117 Pro-Thr
9614 a-t COIII no change
9656 t-c COIII no change
10152 g-c ND3 32 Glu-Gln
10325 g-a ND3 no change
10754 a-c ND4L no change
10775 g-a ND4 6 Val-Ile
10973 c-a ND4 72 Leu-Ile
11151 c-t ND4 131 Ala-Val
11354 t-c ND4 199 Tyr-His
11566 a-g ND4 no change
11617 t-c ND4 no change
11911 c-a ND4 no change
11928 a-g ND4 390 Asn-Ser
12879 t-c ND5 no change
12953 c-t ND5 206 Ala-Val
12954 t-c ND5 no change
12976 c-g ND5 214 Leu-Val
13129 c-t ND5 265 Pro-Ser
13132 c-t ND5 no change
13260 t-c ND5 no change
13264 c-t ND5 no changeBMC Endocrine Disorders 2007, 7:8 http://www.biomedcentral.com/1472-6823/7/8
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13392 t-c ND5 no change
13422 a-g ND5 no change
13708 g-a ND5 458 Ala-Thr
13743 t-c ND5 no change
14364 g-a ND6 no change
14581 t-c ND6 no change
14694 c-g Gln tRNA n/a
14814 c-g CYTB 23 Thr-Ser
14869 g-c CYTB no change
15148 g-a CYTB no change
15172 g-a CYTB no change
15391 c-t CYTB no change
15544 c-a CYTB no change
15629 t-c CYTB no change
15661 c-t CYTB no change
15697 t-g CYTB 317 Phe-Leu
15709 c-g CYTB 321 Ser-STOP
15783 c-t CYTB 346 Pro-Leu
16478 c-t non-coding n/a
16521 a-c non-coding n/a
Table 1: Novel germline sequence variants identified by this study (Continued)
Table 2: Summary of somatic mutations identified in parathyroid adenomas
Tumor ID Tumor Type Mutation Gene affected Expected Protein Change Previously seen?
1 Oxyphil cell 12631T>C ND5 99Ser>Pro normal variant
2 Oxyphil cell 3173G>A 16S rRNA novel
6869C>T CO1 no change somatic mutation-cancer cell line
12425delA ND5 30Asn>Frameshift novel
3 Oxyphil cell 559G>A* D-loop normal variant
7028T CO1 no change normal variant
4 Oxyphil cell 3572insC ND1 89Leu>Frameshift novel
5 Oxyphil cell 15924A>G Thr tRNA LIMM
6 Oxyphil cell 304C>T D-loop normal variant
11038delA ND4 93Lys>Frameshift novel
7 Oxyphil cell 310insC D-loop normal variant
8 Oxyphil cell 3566insC ND1 87Thr>Frameshift novel
9 Oxyphil Cell 4172T>C ND1 289Leu>Pro novel
5026A>G ND2 186His>Arg somatic mutation-oral cancer
10522G>A ND4L 18Gly>Glu novel
12372G>A ND5 no change normal variant
10 Chief Cell 11038delA ND4 93K>Frameshift novel
13577T>C ND5 414Ile>Thr novel
14386T>C ND6 no change normal variant
11 Chief Cell 16311T>C D-loop normal variant
12 Chief Cell 12382A>G ND5 16Ile>Val novel
13 Chief Cell 15578T>C CYTB 278Tyr>His novel
14 Chief Cell 8281del8 non-coding novel
12753A>G ND5 no change novel
14488delT ND6 62Gly>Frameshift novel
16519T>C D-loop normal variant
15 Chief Cell 253C>A D-loop somatic mutation
* indicates that this mutation appeared to be heteroplasmic
LIMM-Lethal Infantile Mitochondrial MyopathyBMC Endocrine Disorders 2007, 7:8 http://www.biomedcentral.com/1472-6823/7/8
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plasmy in a sub-population of the tumor's cells, since
each tumor's cells are being analyzed collectively rather
than on an individual cell-by-cell basis.
Mutations affecting Complex I genes, which represent
38.2% of the mitochondrial genome, accounted for
55.6% of all mutations and 22.2% of mutations occurred
in the highly variable D-loop region.
To determine if the observed trend towards increased
numbers of likely or potentially functionally significant
mtDNA mutations in oxyphil adenomas as compared to
chief cell adenomas was statistically significant, Fisher's
Exact test was performed yielding a significant p-value of
0.02.
No somatic mutations occurred in any of the hyperplastic
parathyroid glands. The one normal parathyroid for
which paired thyroid tissue was available also contained
no somatic mutations. No clustering of germline
sequence variants occurred in any of the samples studied.
Discussion
Mitochondrial abnormalities have been observed in many
cancers and previous studies have demonstrated altered
energy metabolism in cancer cells [2-10]. Homoplasmic
somatic mutations of the mitochondrial genome have
been identified in various tumor types. The mitochondrial
genome is an especially attractive potential target for
mutations that could drive tumorigenesis in a low turno-
ver tissue such as the human parathyroid, given the fre-
quent replication of mitochondrial DNA, independent of
the nuclear genome and the enhanced potential for mito-
chondrial DNA damage by ROS. One might expect an
increased potential for accumulation of somatic muta-
tions in the mitochondrial genome in such low replicative
tissues as the parathyroid over many years. Our data pro-
vide initial support for these hypotheses, and suggest that
other slow-growing tumors arising from low-replication
tissues should be similarly analyzed.
Mitochondrial DNA mutations in parathyroid adenomas
tend to affect Complex I genes more often than other
tumor types and more often then expected by chance
alone. Additionally, D-loop mutations appear to be
underrepresented in parathyroid adenomas compared to
other tumor types. In contrast to many other studies, this
study rigorously examines the entire mitochondrial
genome in matched tumor/normal pairs from the same
individual while many analogous studies of other types of
tumors focused primarily on coding regions and/or the D-
loop region or used population rather than control DNA
from the same patient. Due to the wide range of mutation
frequencies in the literature and discrepancies in study
design, statistical analyses between our data and those
from other related studies cannot generally be performed.
The importance of observed differences between parathy-
roid adenomas and other tumor types remains unclear.
Our results raise the possibility that NADH dehydroge-
nase subunit genes might play a key role in tumorigenesis,
perhaps especially in low-replication tissues. Few studies
have directly examined this issue. The contribution of spe-
cific mtDNA mutations, affecting the ATP synthase subu-
nit 6 [21,22], to tumorigenesis has been examined,
however little is known about the potential pathogenetic
significance of the majority of mtDNA mutations identi-
fied to date. The contribution of specific germline
sequence variants as predisposition alleles to specific
tumor types has been suggested, however the majority of
germline mtDNA sequence variants appear unlikely to
directly contribute to tumorigenesis because of the fre-
quency of such changes in individuals without tumors.
Muller-Hocker, et al. examined respiratory chain function
in normal parathyroid glands and hyperplastic parathy-
roids in uremic patients[23], finding defects in Complex
III and IV in both normal and diseased glands. They also
reported that chief cells in 20% of uremia-associated (sec-
ondary) hyperplastic parathyroid glands had defects of
the respiratory chain, and that heart and muscle cells had
more respiratory chain defects than parathyroid oxyphil
cells. Together with reports of respiratory chain defects in
normal, adenomatous, and hyperplastic parathyroid
glands, the preferential clustering within NADH dehydro-
Schematic diagram of the mitochondrial genome including  locations of the somatic mutations identified in this study Figure 2
Schematic diagram of the mitochondrial genome including 
locations of the somatic mutations identified in this study. 
Locations of somatic mutations in parathyroid chief cell and 
oxyphil cell adenomas are indicated by white and black stars, 
respectively.BMC Endocrine Disorders 2007, 7:8 http://www.biomedcentral.com/1472-6823/7/8
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genase subunit genes of the somatic mitochondrial muta-
tions in our series of adenomas reinforces the intriguing
suspicion that these mutations may be playing an integral
role in parathyroid tumorigenesis. Given that mitochon-
dria have recently been implicated in the regulation of
intracellular calcium homeostasis [24,25] and apoptosis
[26], and that calcium sensing and signaling are crucial to
parathyroid function and regulated PTH secretion, the
possible relationship between calcium homeostasis and
mitochondrial complex I enzyme function deserves fur-
ther scrutiny.
Our data also provide additional support for the hypoth-
esis that mitochondria accumulate in oxyphil cells due to
abnormalities of the mitochondrial genome. Previous
studies of Hurthle cell [27] and other oncocytic tumors
[28] have demonstrated an association between a large
deletion of mtDNA (∆4977) and oncocytic/oxyphilic
tumors in comparison to non-oncocytic tumors of the
same tissue type. However, given its presence in both nor-
mal and tumor cells of various tissues, the potential
pathogenetic significance of such a finding remains
unclear. As such, the presence or absence of this deletion
was not addressed by our experimental approach and was
considered beyond the scope of this manuscript. Func-
tioning oxyphil cell parathyroid adenomas are more likely
to contain somatic mtDNA mutations than chief cell ade-
nomas and the somatic mutations in oxyphil adenomas
are more likely to be functionally significant. These differ-
ences between oxyphil and chief cell adenomas are statis-
tically significant with a p-value of 0.02 (Fisher's Exact
Test). Our results show marked similarity to the recent
findings in thyroid tumors by Gasparre et al that disrup-
tive mutations (nonsense and frameshift mutations) in
Complex I genes are associated with an oncocytic pheno-
type [29]. It is therefore quite plausible that these molec-
ular genetic lesions may make key contributions to
determining the oxyphilic phenotype, as mitochondria
may increase their replication rate as a compensatory
mechanism for altered energy metabolism due to mtDNA
mutations. Further studies of normal oxyphil cells that
could shed additional light on this hypothesis should be
encouraged.
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